Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + clofarabine + busulfan + ATG + TBI
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, External Beam Radiation
01
Overview
This is a multi-agent conditioning regimen used prior to allogeneic hematopoietic cell transplantation, particularly for patients with hematologic malignancies such as acute myeloid leukemia and acute lymphoblastic leukemia. The regimen combines two nucleoside analogs—fludarabine and clofarabine—which inhibit DNA synthesis and repair, leading to complex DNA damage in malignant cells. Busulfan, an alkylating agent, further induces DNA cross-linking and cytotoxicity. Antithymocyte globulin (ATG) is included for immunosuppression to prevent graft rejection by depleting host T-cells. Total body irradiation (TBI) provides additional myeloablative effect and immunosuppression. This combination aims to maximize cytoreduction of malignant cells while providing sufficient immunoablation for successful engraftment[1][2][6].
- Other names
- Flu (for fludarabine)Clo (for clofarabine)Bu (for busulfan)antithymocyte globulin (ATG)total body irradiation (TBI)
02
Targets
DNA polymerase familyCD4 (T lymphocyte surface antigen)RNR (Ribonucleotide reductase)CD8A (CD8 alpha/beta Coreceptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on fludarabine + clofarabine + busulfan + ATG + TBI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + clofarabine + busulfan + ATG + TBI.